CARD9 and pneumocystosis: We have demonstrated the importance of the CARD9 pathway in PCP as well as the ability to target the protein with a specific small molecule inhibitor (termed BRD5529), resulting in a reduction in proinflammatory responses to fungal β-glucan challenge both in vitro and in vivo (27, 28).